Pfizer (NYSE:PFE) Trading Up 2.1%

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) were up 2.1% on Monday . The company traded as high as $28.65 and last traded at $28.59. Approximately 9,699,893 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 43,017,234 shares. The stock had previously closed at $28.01.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective on the stock. Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a research report on Thursday, May 2nd. BMO Capital Markets reiterated an "outperform" rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Argus downgraded Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and a consensus target price of $35.86.

Pfizer Trading Up 1.6 %

The company has a 50 day simple moving average of $27.00 and a 200 day simple moving average of $28.06. The company has a market capitalization of $161.24 billion, a PE ratio of -474.25, a price-to-earnings-growth ratio of 1.18 and a beta of 0.63. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to analysts' expectations of $13.87 billion. During the same period in the previous year, the business earned $1.23 earnings per share. The firm's revenue for the quarter was down 19.5% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.39 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 5.90%. Pfizer's dividend payout ratio is presently -2,799.53%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently added to or reduced their stakes in the stock. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the 3rd quarter valued at $30,000. Mizuho Securities Co. Ltd. purchased a new position in Pfizer during the third quarter worth about $34,000. VisionPoint Advisory Group LLC increased its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC boosted its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 811 shares during the period. Finally, Creekmur Asset Management LLC acquired a new stake in Pfizer in the 4th quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.